Clinitech Laboratory Limited (BOM:544220)
India · Delayed Price · Currency is INR 35.10
-1.50 (-4.10%)
At close: Sep 1, 2026
Clinitech Laboratory Balance Sheet
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Assets
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Equivalents | 21.12 | 30.75 | 7.01 | 7.84 | 1.04 |
Cash & Short-Term Investments | 21.12 | 30.75 | 7.01 | 7.84 | 1.04 |
Cash Growth | -31.31% | 338.44% | -10.49% | 656.27% | -67.66% |
Accounts Receivable | 18.55 | 15.41 | 5.98 | 4.89 | 3.64 |
Other Receivables | 0.01 | - | 0.38 | - | - |
Receivables | 18.56 | 15.41 | 6.36 | 4.89 | 3.64 |
Inventory | 7.31 | 5.29 | 2.84 | 1.41 | 1.56 |
Prepaid Expenses | 0.52 | 0.24 | 0.29 | 0.13 | 0.19 |
Other Current Assets | 26.24 | 22.98 | 10.6 | 5.38 | 7.41 |
Total Current Assets | 73.75 | 74.66 | 27.11 | 19.64 | 13.84 |
Property, Plant & Equipment | 23.99 | 21.19 | 17.07 | 18.82 | 20.53 |
Long-Term Investments | 1.65 | 0.73 | 0.73 | 1.28 | 1.4 |
Other Intangible Assets | 10.31 | 10.15 | 9.5 | 0.08 | 0.03 |
Long-Term Deferred Tax Assets | 1.99 | 1.67 | 1.67 | 1.57 | 1.08 |
Long-Term Deferred Charges | 0.11 | - | - | - | - |
Other Long-Term Assets | - | - | - | 18.94 | - |
Total Assets | 111.79 | 108.4 | 56.08 | 60.33 | 36.87 |
Liabilities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Accounts Payable | 4.84 | 7.55 | 3.46 | 4 | 5.19 |
Accrued Expenses | 3.41 | 6.3 | 4.09 | 4.02 | 1.89 |
Short-Term Debt | - | - | 5.88 | 6.71 | 4.57 |
Current Portion of Long-Term Debt | - | - | 0.42 | 0.76 | 0.72 |
Current Income Taxes Payable | 1.62 | 2.72 | 1.43 | - | - |
Other Current Liabilities | 1.48 | 1.55 | 1.04 | 2.08 | 1.25 |
Total Current Liabilities | 11.35 | 18.11 | 16.32 | 17.57 | 13.62 |
Long-Term Debt | 5.38 | - | 2.34 | 2.82 | 3.57 |
Long-Term Unearned Revenue | - | - | - | 14.9 | - |
Pension & Post-Retirement Benefits | 2.53 | 1.99 | 1.95 | 1.23 | 1.21 |
Other Long-Term Liabilities | - | - | - | 0 | - |
Total Liabilities | 19.26 | 20.1 | 20.6 | 36.53 | 18.39 |
Shareholders' Equity
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Common Stock | 22.82 | 22.82 | 16.8 | 15 | 15 |
Additional Paid-In Capital | 47.89 | 47.89 | 5.04 | - | - |
Retained Earnings | 21.77 | 17.59 | 13.64 | 8.81 | 3.48 |
Total Common Equity | 92.48 | 88.3 | 35.48 | 23.81 | 18.48 |
Minority Interest | 0.05 | - | - | - | - |
Shareholders' Equity | 92.53 | 88.3 | 35.48 | 23.81 | 18.48 |
Total Liabilities & Equity | 111.79 | 108.4 | 56.08 | 60.33 | 36.87 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Total Debt | 5.38 | - | 8.63 | 10.29 | 8.86 |
Net Cash (Debt) | 15.75 | 30.75 | -1.62 | -2.46 | -7.83 |
Net Cash Growth | -48.79% | - | - | - | - |
Net Cash Per Share | 6.90 | 14.77 | -1.03 | -1.64 | -5.22 |
Filing Date Shares Outstanding | 2.28 | 2.28 | 2.28 | 1.5 | 1.5 |
Total Common Shares Outstanding | 2.28 | 2.28 | 2.28 | 1.5 | 1.5 |
Working Capital | 62.4 | 56.55 | 10.8 | 2.07 | 0.22 |
Book Value Per Share | 40.52 | 38.69 | 15.55 | 15.87 | 12.32 |
Tangible Book Value | 82.17 | 78.15 | 25.98 | 23.73 | 18.45 |
Tangible Book Value Per Share | 36.00 | 34.24 | 11.38 | 15.82 | 12.30 |
Machinery | 58.01 | 52.68 | 44.09 | 35.9 | 34.74 |
Construction In Progress | 2.55 | - | - | 5.6 | 4.05 |